Long-term results of a phase 2 RCT | Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma.
15 Aug, 2022 | 11:46h | UTCOriginal Study: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine